|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Changes in EEG** | |  | **Seizure frequency before ASMs** | | |  | **Seizure frequency after ASMs** | | |  |
|  | No change/Deterioration | Improvement between 25-100% | p value | No seizure/Single seizure | Once or more per month | Once or more per week /Everyday | p value | No seizure/Single seizure | Once or more per month | Once or more per week /Everyday | p value |
|  |  | n (%) | n (%) |  | n (%) | n (%) | n (%) |  | n (%) | n (%) | n (%) |  |
|  | **Clinical stage** | | | | | | | | | | | |
|  | Stage 1 | 13 (81,3) | 3 (18,8) | **0,025** | 3 (18,8) | 9 (56,3) | 4 (25,0) | NA | 1 (6,3) | 11 (68,8) | 4 (25,0) | NA |
|  | Stage 2 | 10 (62,5) | 6 (37,5) | 2 (12,5) | 9 (56,3) | 5 (31,3) | 1 (6,3) | 11 (68,8) | 4 (25,0) |
|  | Stage 3 | 16 (42,1) | 22 (57,9) | 7 (18,4) | 25 (65,8) | 6 (15,8) | 3 (7,9) | 29 (76,3) | 6 (15,8) |
|  | **Comorbidity** | | | | | | | | | | | |
|  | Yes | 12 (70,6) | 5 (29,4) | 0,156 | 9 (17,0) | 31 (58,5) | 13 (24,5) | NA | 5 (9,4) | 38 (71,7) | 10 (18,9) | NA |
|  | No | 27 (50,9) | 26 (49,1) | 3 (17,6) | 12 (70,6) | 2 (11,8) | 0 (0,0) | 13 (76,5) | 4 (23,5) |
|  | **Genetic mutation type** | | | | | | | | | | | |
|  | SCN1A Heterozygous | 35 (56,5) | 27 (43,5) | 1,000 | 11 (17,7) | 38 (61,3) | 13 (21,0) | NA | 4 (6,5) | 44 (71,0) | 14 (22,6) | NA |
|  | Other types of mutations | 4 (50,0) | 4 (50,0) | 1 (12,5) | 5 (62,5) | 2 (25,0) | 1 (12,5) | 7 (87,5) | 0 (0,0) |
|  | **İlk EEG** | | | | | | | | | | | |
|  | Normal | 18 (64,3) | 10 (35,7) | 0,238 | 3 (10,7) | 24 (85,7) | 1 (3,6) | **0,002** | 3 (10,7) | 23 (82,1) | 2 (7,1) | NA |
|  | There is a finding (Focal/Generalized/Multifocal) | 21 (50,0) | 21 (50,0) | 9 (21,4) | 19 (45,2) | 14 (33,3) | 2 (4,8) | 28 (66,7) | 12 (28,6) |
|  | **Change in seizure duration after ASMs** | | | | | | | | | | | |
|  | Yes | 26 (51,0) | 25 (49,0) | 0,191 | 8 (15,7) | 32 (62,7) | 11 (21,6) | NA | 4 (7,8) | 37 (72,5) | 10 (19,6) | NA |
|  | No | 13 (68,4) | 6 (31,6) | 4 (21,1) | 11 (57,9) | 4 (21,1) | 1 (5,3) | 14 (73,7) | 4 (21,1) |
|  | **Changes in seizure semiology after ASM** | | | | | | | | | | | |
|  | Yes | 23 (52,3) | 21 (47,7) | 0,451 | 8 (18,2) | 26 (59,1) | 10 (22,7) | 0,872 | 3 (6,8) | 22 (75,0) | 8 (18,2) | NA |
|  | Var | 16 (61,5) | 10 (38,5) | 4 (15,4) | 17 (65,4) | 5 (19,2) | 2 (7,7) | 18 (69,2) | 6 (23,1) |
|  | **Cognitive recovery after ASM** | | | | | | | | | | | |
|  | Yes | 8 (50,0) | 8 (50,0) | 0,600 | 3 (18,8) | 8 (50,0) | 5 (31,3) | NA | 0 (0,0) | 13 (81,3) | 3 (18,8) | NA |
|  | No | 31 (57,4) | 23 (42,6) | 9 (16,7) | 35 (64,8) | 10 (18,5) | 5 (9,3) | 38 (70,4) | 11 (20,4) |
|  | Table -1: Comparison of the data before and after initiation of ASMs. | | | | | | | | | | | |

**Table 2: ASMs effective on seizure frequency and duration**

|  |  |  |  |
| --- | --- | --- | --- |
| **Medications which reduce the frequency of seizures** | | **Medications which reduce seizure duration** | |
|  | **n (%)** |  | **n (%)** |
| **Clobazam** | 30 (41,4) | **Clobazam** | 20 (28,6) |
| **Valproate** | 8 (11,4) | **Valproate** | 13 (17,1) |
| **Topiramate** | 7 (8,6) | **Stiripentol** | 10 (14,3) |
| **Stiripentol** | 5 (4,3) | **Topiramate** | 5 (5,7) |
| **Other drugs** | 10 (34,3) | **other drugs** | 7 (34,3) |
| **Total** | **60 (100)** | **Total** | **55 (100)** |

**Table 3: Seizure frequency rates with ASMs**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | | **Seizure frequency after ASMs** | | | |  |
| Nöbet yok/Tek nöbet | Once or more per month | Once or more per week /Everyday | Total | p value |
| **Seizure frequency before ASMs** | No seizure/Single seizure | 1 | 11 | 0 | 12 | 0,134 |
| Once or more per month | 3 | 33 | 7 | 43 |
| Once or more per week /Everyday | 1 | 7 | 7 | 15 |
|  | **Total** | **5** | **51** | **14** | **70** |